- Home
- NNAVW vs SNY Comparison
NNAVW vs SNY Comparison
Compare NNAVW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNAVW
- SNY
- Stock Information
- Founded
- NNAVW 2007
- SNY 1994
- Country
- NNAVW United States
- SNY France
- Employees
- NNAVW 96
- SNY N/A
- Industry
- NNAVW Industrial Machinery/Components
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- NNAVW Industrials
- SNY Health Care
- Exchange
- NNAVW Nasdaq
- SNY Nasdaq
- Market Cap
- NNAVW N/A
- SNY 113.4B
- IPO Year
- NNAVW N/A
- SNY N/A
- Fundamental
- Price
- NNAVW $7.17
- SNY $47.03
- Analyst Decision
- NNAVW
- SNY Buy
- Analyst Count
- NNAVW 0
- SNY 4
- Target Price
- NNAVW N/A
- SNY $61.50
- AVG Volume (30 Days)
- NNAVW 53.1K
- SNY 2.8M
- Earning Date
- NNAVW 03-12-2025
- SNY 10-24-2025
- Dividend Yield
- NNAVW N/A
- SNY 3.40%
- EPS Growth
- NNAVW N/A
- SNY 118.56
- EPS
- NNAVW N/A
- SNY 8.65
- Revenue
- NNAVW $4,963,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- NNAVW N/A
- SNY $2.01
- Revenue Next Year
- NNAVW N/A
- SNY $6.82
- P/E Ratio
- NNAVW N/A
- SNY $5.44
- Revenue Growth
- NNAVW 43.44
- SNY 15.65
- 52 Week Low
- NNAVW $4.47
- SNY $44.73
- 52 Week High
- NNAVW $4.70
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- NNAVW N/A
- SNY 42.55
- Support Level
- NNAVW N/A
- SNY $46.79
- Resistance Level
- NNAVW N/A
- SNY $47.69
- Average True Range (ATR)
- NNAVW 0.00
- SNY 0.71
- MACD
- NNAVW 0.00
- SNY -0.27
- Stochastic Oscillator
- NNAVW 0.00
- SNY 32.62
About NNAVW NextNav Inc. Warrant
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.